Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months in this group. Daniel Pollyea, MD, MS, shares results from this phase 1 study.
Recent Articles
Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML
Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a susbset do not...
Is Chronic Lymphocytic Leukemia Curable?
Chronic lymphocytic leukemia (CLL) has long been considered an incurable disease. The goal of traditional frontline treatments is to minimize disease burden and allow...
Summertime Blues
At the time of writing this column, the calendar has just turned to August and another July has come and gone. There’s plenty of...
Private-Sector Funding Presents Ethical Problems for NIH
To strengthen funding for the National Institutes of Health (NIH) in the 1990s, U.S. Congress created the Foundation of the National Institutes of Health...
Pharmaceutical Lobbying Group Funnels “Dark Money” to Sway Policy
An investigation by Kaiser Health News revealed that the Pharmaceutical Research and Manufacturers of America (PhRMA) quietly gave millions of dollars to groups that...
Current Issue
August 2018, Volume 4, Issue 10
This issue features a look at direct-to-consumer pharmaceutical advertising, advice to graduating hematologists, and more.
